News | February 07, 2025
Akums reports Q3 FY25 adjusted PAT at Rs. 66.3 Cr
Branded formulation business continues to perform well across domestic and export markets
Branded formulation business continues to perform well across domestic and export markets
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment
Backed by Semaglutide launches, the company reported 47% quarter-on-quarter revenue growth in Q4 FY26, with EBITDA expanding more than fivefold
The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
HCG clinicians contributing to one of the largest bodies of oncology research from India
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
Net profit for the quarter grew by 254.2 per cent and stood at Rs. 20.9 crore
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
